These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 26475406)

  • 1. Thromboembolism as the adverse event of combined oral contraceptives in Japan.
    Sugiura K; Kobayashi T; Ojima T
    Thromb Res; 2015 Dec; 136(6):1110-5. PubMed ID: 26475406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risks of thromboembolism associated with hormone contraceptives in Japanese compared with Western women.
    Kobayashi T; Sugiura K; Ojima T
    J Obstet Gynaecol Res; 2017 May; 43(5):789-797. PubMed ID: 28422361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The epidemiological characteristics of thromboembolism related to oral contraceptives in Japan: Results of a national survey.
    Sugiura K; Kobayashi T; Ojima T
    J Obstet Gynaecol Res; 2021 Jan; 47(1):198-207. PubMed ID: 32885566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The incidence and prognosis of thromboembolism associated with oral contraceptives: Age-dependent difference in Japanese population.
    Sugiura K; Ojima T; Urano T; Kobayashi T
    J Obstet Gynaecol Res; 2018 Sep; 44(9):1766-1772. PubMed ID: 29998477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risks of thromboembolism associated with hormonal contraceptives related to body mass index and aging in Japanese women.
    Sugiura K; Kobayashi T; Ojima T
    Thromb Res; 2016 Jan; 137():11-16. PubMed ID: 26672897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonoral combined hormonal contraceptives and thromboembolism: a systematic review.
    Tepper NK; Dragoman MV; Gaffield ME; Curtis KM
    Contraception; 2017 Feb; 95(2):130-139. PubMed ID: 27771476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of venous thromboembolism with drospirenone in combined oral contraceptive products.
    Sehovic N; Smith KP
    Ann Pharmacother; 2010 May; 44(5):898-903. PubMed ID: 20371756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Risk for Venous Thromboembolism With Use of Low-Dose Extended- and Continuous-Cycle Combined Oral Contraceptives: A Safety Study Using the Sentinel Distributed Database.
    Li J; Panucci G; Moeny D; Liu W; Maro JC; Toh S; Huang TY
    JAMA Intern Med; 2018 Nov; 178(11):1482-1488. PubMed ID: 30285041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of venous thromboembolism in young Swedish women and possibly preventable cases among combined oral contraceptive users.
    Samuelsson E; Hägg S
    Acta Obstet Gynecol Scand; 2004 Jul; 83(7):674-81. PubMed ID: 15225194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Venous thromboembolism and combined oral contraceptives. Reported adverse reactions indicate at least similar risk with the most recent contraceptive pills].
    Kieler H; Persson I; Odlind V
    Lakartidningen; 2003 Sep; 100(39):3050-2. PubMed ID: 14560670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of combined oral contraceptives and risk of venous thromboembolism in young women: a nested case-control analysis using German claims data.
    Schink T; Princk C; Braitmaier M; Haug U
    BJOG; 2022 Dec; 129(13):2107-2116. PubMed ID: 35876787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progestin-only contraception and venous thromboembolism.
    Blanco-Molina MA; Lozano M; Cano A; Cristobal I; Pallardo LP; Lete I
    Thromb Res; 2012 May; 129(5):e257-62. PubMed ID: 22425318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drospirenone-containing combined oral contraceptives and the risk of arterial thrombosis: a population-based nested case-control study.
    Larivée N; Suissa S; Eberg M; Joseph L; Eisenberg MJ; Abenhaim HA; Filion KB
    BJOG; 2017 Oct; 124(11):1672-1679. PubMed ID: 27704723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of recurrent venous thromboembolism among young women after a first event while exposed to combined oral contraception versus not exposed to: a cohort study.
    Le Moigne E; Delluc A; Tromeur C; Nowak E; Mottier D; Lacut K; Le Gal G
    Thromb Res; 2013 Jul; 132(1):51-5. PubMed ID: 23786893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives.
    Farmer RD; Lawrenson RA; Todd JC; Williams TJ; MacRae KD; Tyrer F; Leydon GM
    Br J Clin Pharmacol; 2000 Jun; 49(6):580-90. PubMed ID: 10848722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary embolism associated with combined oral contraceptives: reporting incidences and potential risk factors for a fatal outcome.
    Hedenmalm K; Samuelsson E; Spigset O
    Acta Obstet Gynecol Scand; 2004 Jun; 83(6):576-85. PubMed ID: 15144341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombotic risks of oral contraceptives.
    Rott H
    Curr Opin Obstet Gynecol; 2012 Aug; 24(4):235-40. PubMed ID: 22729096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of estrogen type on cardiovascular safety of combined oral contraceptives.
    Dinger J; Do Minh T; Heinemann K
    Contraception; 2016 Oct; 94(4):328-39. PubMed ID: 27343748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives.
    Dinger J; Bardenheuer K; Heinemann K
    Contraception; 2014 Apr; 89(4):253-63. PubMed ID: 24576793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined hormonal contraceptive use among obese women and risk for cardiovascular events: A systematic review.
    Horton LG; Simmons KB; Curtis KM
    Contraception; 2016 Dec; 94(6):590-604. PubMed ID: 27263039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.